1. Home
  2. GPCR vs CODI Comparison

GPCR vs CODI Comparison

Compare GPCR & CODI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPCR
  • CODI
  • Stock Information
  • Founded
  • GPCR 2016
  • CODI 2005
  • Country
  • GPCR United States
  • CODI United States
  • Employees
  • GPCR N/A
  • CODI N/A
  • Industry
  • GPCR
  • CODI Home Furnishings
  • Sector
  • GPCR
  • CODI Consumer Discretionary
  • Exchange
  • GPCR Nasdaq
  • CODI Nasdaq
  • Market Cap
  • GPCR 1.8B
  • CODI 1.8B
  • IPO Year
  • GPCR 2023
  • CODI 2006
  • Fundamental
  • Price
  • GPCR $27.03
  • CODI $23.90
  • Analyst Decision
  • GPCR Buy
  • CODI Strong Buy
  • Analyst Count
  • GPCR 6
  • CODI 3
  • Target Price
  • GPCR $85.67
  • CODI $29.00
  • AVG Volume (30 Days)
  • GPCR 797.2K
  • CODI 200.3K
  • Earning Date
  • GPCR 11-13-2024
  • CODI 10-30-2024
  • Dividend Yield
  • GPCR N/A
  • CODI 4.18%
  • EPS Growth
  • GPCR N/A
  • CODI 38.85
  • EPS
  • GPCR N/A
  • CODI 0.56
  • Revenue
  • GPCR N/A
  • CODI $2,216,497,000.00
  • Revenue This Year
  • GPCR N/A
  • CODI $13.12
  • Revenue Next Year
  • GPCR N/A
  • CODI $8.93
  • P/E Ratio
  • GPCR N/A
  • CODI $42.26
  • Revenue Growth
  • GPCR N/A
  • CODI 16.71
  • 52 Week Low
  • GPCR $29.48
  • CODI $19.76
  • 52 Week High
  • GPCR $62.74
  • CODI $25.07
  • Technical
  • Relative Strength Index (RSI)
  • GPCR 35.94
  • CODI 57.27
  • Support Level
  • GPCR $30.81
  • CODI $23.55
  • Resistance Level
  • GPCR $36.42
  • CODI $24.32
  • Average True Range (ATR)
  • GPCR 2.10
  • CODI 0.41
  • MACD
  • GPCR -0.15
  • CODI -0.04
  • Stochastic Oscillator
  • GPCR 25.07
  • CODI 58.12

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

About CODI D/B/A Compass Diversified Holdings Shares of Beneficial Interest

Compass Diversified Holdings is a diversified business conglomerate based in the United States having two groups: branded consumer business and industrial business. Branded consumer businesses are characterized as those businesses that capitalize on a valuable brand name in their respective market sector. It includes 5.11, Ergobaby, Liberty Safe, and Velocity Outdoor. Industrial businesses are characterized as those businesses that focus on manufacturing and selling particular products and industrial services within a specific market sector. The company has operations in the United States, Canada, Europe, Asia Pacific, and other International areas.

Share on Social Networks: